Annexon Biosciences Q2 net loss widens, cash runway extended - ANNX News | RalliesAnnexon Biosciences Q2 net loss widens, cash runway extended
A
ANNX• Outlook
- Annexon expects BLA submission for tanruprubart in GBS in Q4 2026
- Company sees Month 15 primary endpoint data for vonaprument in GA in Q4 2026
- Annexon anticipates proof-of-concept data for ANX1502 in CAD in Fall 2026
Overview
- U.S. neuroinflammatory drug developer's Q2 net loss widened yr/yr, loss per share rose
- Cash and investments totaled $209.2 mln, runway extended into 2028 with new credit facility
- Company increased R&D and G&A expenses due to clinical trials and consulting costs
Key Details
| | | |
|---|
| Metric | Beat/Miss | Actual | Consensus Estimate |
| Q2 Loss Per Share | | $0.28 | |
| Q2 Net Loss | | $55.35 mln | |
| Q2 Cash & Investments | | $209.20 mln | |
| Q2 Income From Operations | | -$57.23 mln | |
| Q2 Loss Per Basic Share | | $0.28 | |
| Q2 Operating Expenses | | $57.23 mln | |
Result Drivers
- R&D SPENDING - Higher R&D expenses mainly due to Phase 3 ARCHER II trial of vonaprument in GA and contract manufacturing costs for product candidates
PLX
•
